title: [A system of prescriptions without drug approval: example of baclofen].
abstract: Baclofen is an anti-spastic drug that acts as an agonist of GABA-B receptors. It also seems to decrease the appetence for alcohol (anti-craving effect), although this effect has not been certified by Authorities for drug approval in France (AMM). However, baclofen receives a great deal of demand by patients hoping to reduce their alcohol consumption. Nonetheless, the lack of AMM and the high doses of baclofen supposed to exert an anti-craving effect often discourage practitioners from prescribing this drug in current medical practice. Therefore, it is preferable for a drug like baclofen to be prescribed under specific regulations. As such, certain criteria similar to those required in clinical trials are necessary to protect patients as well as the prescribing doctors. The criteria that are proposed here are: the use of drugs without AMM approval as a last resort (all other treatments must have failed), the collegiate decision for the drug prescription, good knowledge of the potency of the drug as well as good record keeping of patients and proper supervision. The departments of addiction, pharmacology and pharmacovigilance of the University Hospital of Lille, France present here a medical process named "multidisciplinary consultations for resort treatments of addictions" (CAMTEA). This process is designed to meet all the above mentioned criteria and to allow the use of baclofen as an anti-craving drug in safest conditions. If this proves to be successful with baclofen, it is possible to extend the use of CAMTEA to other drugs without AMM approval in addictologic pathologies.
authors.affiliation: Service d'Addictologie, Université Lille Nord de France, CHRU, Lille, France.
authors.forename: Benjamin
authors.initials: B
authors.lastname: Rolland
authors.forename: Sylvie
authors.initials: S
authors.lastname: Deheul
authors.forename: Thierry
authors.initials: T
authors.lastname: Danel
authors.forename: Régis
authors.initials: R
authors.lastname: Bordet
authors.forename: Olivier
authors.initials: O
authors.lastname: Cottencin
mesh_terms: D000437:Alcoholism / Q000188:drug therapy* / Q000523:psychology; D001418:Baclofen / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D019090:Case Management; D017277:Drug Approval; D011307:Drug Prescriptions / Q000592:standards*; D005602:France; D018755:GABA Agonists / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D017408:Guidelines as Topic; D007722:Health Knowledge, Attitudes, Practice; D006785:Hospitals, University; D006801:Humans; D009125:Muscle Relaxants, Central / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D056687:Off-Label Use; D012017:Referral and Consultation; D019966:Substance-Related Disorders / Q000503:physiopathology / Q000523:psychology
chemical_list: D018755:GABA Agonists; D009125:Muscle Relaxants, Central; D001418:Baclofen